Benefits
Stress reduction and emotional regulation (psychobiotic effects)
B. longum 1714 is one of the few probiotics with direct clinical evidence for stress and mood effects in healthy adults. Multiple RCTs (4-week supplementation, 1 billion CFU/day) show reduced cumulative stress responses on the Cold Pressor Test, improved sleep quality, reduced cortisol response to acute stressors, and altered EEG patterns suggesting enhanced emotional processing. Considered the most-studied 'psychobiotic' globally.
IBS symptom improvement (35624 strain)
B. longum 35624 (subspecies infantis, marketed as Align®) demonstrated significant IBS symptom reduction in multiple multicenter RCTs. A landmark trial in 362 women with IBS showed 35624 (10^8 CFU/day) significantly improved abdominal pain/discomfort, bloating, bowel dysfunction, and global IBS symptoms over 4 weeks. Higher and lower doses (10^6, 10^10) were ineffective — strict dose-dependence.
Allergy symptom reduction (BB536 strain)
B. longum BB536 has multiple RCTs showing reductions in seasonal allergic rhinitis (Japanese cedar pollen) symptoms, atopic dermatitis severity in infants, and milk/egg allergic reactions in challenge tests. Mechanism involves Th1/Th2 balance restoration via dendritic cell modulation.
Constipation relief in elderly
B. longum (especially BB536) significantly improves bowel regularity in elderly populations and patients with chronic functional constipation. Effects are most pronounced after 4+ weeks of supplementation. Stool frequency increases and stool consistency normalizes via SCFA production stimulating colonic motility.
Mechanism of action
Vagal nerve signaling for gut-brain axis
B. longum 1714 modulates vagal nerve afferent signaling from the gut to the brainstem, influencing emotional processing centers. Animal studies show vagotomy abolishes psychobiotic effects, confirming vagus nerve as the primary signaling pathway. EEG changes in 1714-supplemented subjects support central nervous system effects.
GABA and tryptophan metabolite production
B. longum produces GABA (the primary inhibitory neurotransmitter in the brain) via glutamate decarboxylase and modulates tryptophan/serotonin metabolism in the gut. While GABA itself doesn't cross the blood-brain barrier well, gut-derived GABA influences enteric nervous system signaling and indirect CNS effects.
HMO (human milk oligosaccharide) utilization
B. longum subspecies infantis is uniquely adapted to metabolize human milk oligosaccharides — a feature shared with very few other gut bacteria. This explains its dominance in breastfed infant guts and its specific value in infant formula/probiotic supplementation. The HMO-utilization gene cluster encodes specialized transporters and glycosidases.
SCFA production and HPA axis modulation
Through fermentation of dietary fibers and HMOs, B. longum produces acetate and lactate, which feed butyrate-producing bacteria. Resulting butyrate crosses gut-blood barrier and modulates HPA axis sensitivity, reducing cortisol reactivity to stressors. This is a likely mechanism for the psychobiotic effects observed clinically.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial. Healthy male adults received B. longum 1714 (10⁹ CFU/day) for 4 weeks vs placebo. Outcomes: cortisol response to acute social stressor, subjective stress, depression and anxiety scales, EEG. (Allen et al. 2016, Transl Psychiatry)
Healthy male adults. 4-week crossover.
B. longum 1714 reduced cumulative cortisol response to social stressor (Cold Pressor Test/Trier-style stressor), improved subjective stress and anxiety scores, and modulated EEG patterns associated with mental vitality. Among earliest 'psychobiotic' RCTs supporting gut-brain axis modulation by specific strains.
Randomized, double-blind, placebo-controlled trial in 362 women with IBS comparing three doses (10⁶, 10⁸, 10¹⁰ CFU/day) of B. infantis 35624 vs placebo over 4 weeks. (Whorwell et al. 2006, Am J Gastroenterol)
362 women with IBS. 4-week intervention.
10⁸ CFU/day dose significantly improved IBS composite symptom score and individual symptoms (pain/discomfort, bloating, bowel dysfunction, incomplete evacuation, straining, gas) vs placebo. Higher 10¹⁰ dose was not superior to 10⁸ — non-monotonic dose-response. Note: B. infantis 35624 is now classified as B. longum subsp. longum 35624 (formerly Align®'s strain).
13-week, randomized, double-blind, placebo-controlled trial during cedar pollen season. 44 Japanese subjects with cedar pollinosis received yogurt with B. longum BB536 (5×10¹⁰ CFU/day) or placebo yogurt. Outcomes: subjective symptoms, eye drop usage, serum cedar-specific IgE. (Xiao et al. 2006, Clin Exp Allergy)
44 cedar-pollen-allergic Japanese adults. 13-week intervention.
Significant reductions in eye symptoms, eye drop usage, throat symptoms, and serum cedar-specific IgE. Effects most pronounced in the latter half of pollen season. Suggests BB536 modulates allergic immune responses. Note: BB536 (Morinaga) is one of the most clinically studied B. longum strains globally.